Pharmaceutical industry in China

Inotiv, Inc. to Report Third Quarter Fiscal 2021 Financial Results and Host Conference Call on Wednesday, August 11, 2021

Retrieved on: 
Thursday, July 22, 2021
Health sciences, Life sciences, Pharmaceutical sciences, Pharmaceutical industry, Pharmacology, Pharmacy, Pharmaceuticals policy, Contract research organizations, Pharmaceutical industry in China, European Federation of Pharmaceutical Industries and Associations

Inotiv, Inc. is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations.

Key Points: 
  • Inotiv, Inc. is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations.
  • The Company focuses on developing innovative services supporting its clients discovery and development objectives for improved decision-making and accelerated goal attainment.
  • The Companys products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market.
  • Visit inotivco.com for more information about the Company.

ANI Pharmaceuticals to Discuss Second Quarter 2021 Financial Results on August 6, 2021

Retrieved on: 
Thursday, July 22, 2021
Biotechnology, Pharmaceutical, Health, Pharmaceuticals policy, Pharmaceutical industry in China, Pharmacy in China, Science and technology in the People's Republic of China

A replay of the conference call will be available within two hours of the calls completion and will remain accessible for one-week by dialing 800-695-0974 and entering access code 5412658.

Key Points: 
  • A replay of the conference call will be available within two hours of the calls completion and will remain accessible for one-week by dialing 800-695-0974 and entering access code 5412658.
  • ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals.
  • We focus on niche and high barrier to entry opportunities including controlled substances, oncology products (anti-cancers), hormones and steroids, and complex formulations.
  • For more information, please visit our website www.anipharmaceuticals.com .

US Pharmaceutical and Healthcare Industry Forecast and Analysis Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021
Health, Pharmaceutical, Health sciences, Health, Contemporary history, Pharmaceutical industry, Pharmacology, Pharmacy, Healthcare industry, COVID-19 pandemic, Pharmaceutical industry in China

The "Pharmaceutical and Healthcare Industry in the US - Forecast and Analysis 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmaceutical and Healthcare Industry in the US - Forecast and Analysis 2021" report has been added to ResearchAndMarkets.com's offering.
  • With the economic slowdown setting in due to the pandemic, the US pharmaceutical and healthcare industry is expected to decelerate in the short term.
  • The report covers the following data:
    An in-depth coverage of the pharmaceutical and healthcare industry in the US by sectors along with an analysis of how the COVID-19 pandemic is effecting the industry.
  • A SWOT analysis of the US pharmaceutical and healthcare industry.

Pharmanovia expands strategic collaboration with M8 Pharmaceuticals in Latin America

Retrieved on: 
Tuesday, July 20, 2021
Life sciences, Health sciences, Biotechnology, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Biopharmaceutical

MEXICO CITY, July 20, 2021 /PRNewswire/ --m8 Pharmaceuticals and Pharmanovia have signed an exclusive licensing agreement for a portfolio of several brands for Mexico & Brazil.

Key Points: 
  • MEXICO CITY, July 20, 2021 /PRNewswire/ --m8 Pharmaceuticals and Pharmanovia have signed an exclusive licensing agreement for a portfolio of several brands for Mexico & Brazil.
  • This collaboration reinforces m8 Pharmaceuticals' and Pharmanovia's mutual focus to strengthen the presence of their medicines in Latin America, bringing innovative and proven treatments with greater access to patients and caregivers throughout the region.
  • Regarding the collaboration Amit Patel, Pharmanovia's CEO said "Having had the pleasure of working with the M8 team in the past, we are looking forward to this extended collaboration that strengthens our position in Latin America.
  • m8 is a specialty biopharmaceutical company focused on licensing, marketing and distributing innovative and established therapeutics in the two largest Latin America markets: Brazil and Mexico.

TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award

Retrieved on: 
Tuesday, July 20, 2021
Companies, Industry economics), PC games, Tracon II, Bayer, Pharmaceutical industry in China

We are very pleased to welcome Brenda to the senior management team at TRACON, said Charles Theuer, M.D., Ph.D., President and CEO of TRACON.

Key Points: 
  • We are very pleased to welcome Brenda to the senior management team at TRACON, said Charles Theuer, M.D., Ph.D., President and CEO of TRACON.
  • Her vast regulatory affairs experience working with the FDA will be instrumental to TRACON as we execute on our plan to complete the ENVASARC trial.
  • Dr. Marczi also held senior roles at Eagle Pharmaceuticals and Berlex (now Bayer AG), where she oversaw the filing of multiple successful New Drug Applications.
  • I am thrilled to join the impressive team at TRACON during such a pivotal time in the Companys development of envafolimab.

India Pharmaceutical and Healthcare Industry Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021
Health, Pharmaceutical, Health sciences, Health, Contemporary history, Pharmaceutical industry, Pharmacology, Pharmacy, COVID-19 pandemic, Pharmaceutical industry in China

The "Pharmaceutical and Healthcare Industry in India - Forecast and Analysis 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmaceutical and Healthcare Industry in India - Forecast and Analysis 2021" report has been added to ResearchAndMarkets.com's offering.
  • There is no doubt that India plays an important position in the global pharmaceutical and healthcare industry.
  • The publisher presents an in-depth analysis of the Pharmaceutical and Healthcare Industry of India in its research report Pharmaceutical and Healthcare Industry in India - Forecast and Analysis 2021.
  • The report covers the following data:
    An in-depth coverage of the pharmaceutical and healthcare industry in India by sectors along with an analysis of how the COVID-19 pandemic is effecting the industry.

Ukraine Pharmaceutical and Healthcare Industry Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021
Hospitals, Pharmaceutical, Health, Health care reform, Pharmaceutical industry, Healthcare industry, Pharmaceutical industry in China

The "Pharmaceutical and Healthcare Industry in Ukraine - Forecast and Analysis 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmaceutical and Healthcare Industry in Ukraine - Forecast and Analysis 2021" report has been added to ResearchAndMarkets.com's offering.
  • The pharmaceutical industry in Ukraine is amongst the ten biggest pharmaceutical industries in the Central and Eastern European (CEE) region.
  • With the country adopting new healthcare reform bills from January 2018, the overall outlook for the healthcare and pharmaceutical industry has improved considerably.
  • The report covers the following data:
    An in-depth coverage of the pharmaceutical and healthcare industry in Ukraine by sectors along with an analysis of how the COVID-19 pandemic is effecting the industry.

Nexus Pharmaceuticals Celebrates Grand Opening of New, State-of-the-Art Manufacturing Facility

Retrieved on: 
Monday, July 19, 2021
Biotechnology, Pharmaceutical, Health, Medical Supplies, Tablet computers, Pleasant Prairie, Wisconsin, Bryan Steil, Google Nexus, Pharmaceutical industry in China, NEXUS, Draft:Nexus Pharmaceuticals, Inc

On Friday, July 16, 2021, Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and domestic pharmaceutical manufacturer, celebrated the opening of Project Tomorrow the companys new, state-of-the-art manufacturing facility in Pleasant Prairie, Wisconsin.

Key Points: 
  • On Friday, July 16, 2021, Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and domestic pharmaceutical manufacturer, celebrated the opening of Project Tomorrow the companys new, state-of-the-art manufacturing facility in Pleasant Prairie, Wisconsin.
  • Wisconsin Governor Tony Evers and U.S. Representative Bryan Steil (WI-01) attended the Project Tomorrow Grand Opening event.
  • Nexus stands ready to support global COVID-19 vaccine productiona capability that will be boosted as a result of this new manufacturing facility.
  • For more information about Nexus Pharmaceuticals, including our new state-of-the-art Wisconsin manufacturing facility, please visit https://www.nexuspharma.net/project-tomorrow/ .

NovaBay Pharmaceuticals Partners with Harrow Health’s ImprimisRx® to Promote Prescription Avenova

Retrieved on: 
Monday, July 19, 2021
Pharmaceutical, Health, Optical, Health care, Pharmaceuticals policy, Medical specialties, Health, Harrow Health, Optometry, Pharmaceutical industry in China, Ophthalmology, Harrow Health, NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®, HARROW HEALTH, NOVABAY PHARMACEUTICALS, INC.: GOING BEYOND ANTIBIOTICS®

(NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces it has partnered with ImprimisRx, one of the nations leading ophthalmology-focused pharmaceutical businesses, to promote prescription Avenova.

Key Points: 
  • (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces it has partnered with ImprimisRx, one of the nations leading ophthalmology-focused pharmaceutical businesses, to promote prescription Avenova.
  • Under the new agreement with ImprimisRx, we can now cost-efficiently expand Avenovas reach within the prescription channel by better engaging with ophthalmologists and optometrists, making prescription Avenova even more accessible than ever before.
  • Avenova is a compelling addition to our expanding ImprimisRx ophthalmic product portfolio, said John Saharek, President of ImprimisRx.
  • Harrow Health also holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries.

Harrow Health Granted Two Patents for Novel Surgical Dilation Formulation

Retrieved on: 
Thursday, July 15, 2021
Harrow Health, Pharmaceutical industry in China, Health care, Health

Harrow Healths wholly owned subsidiary, ImprimisRx, provides surgical dilation (or mydriatic) agents for more than 250,000 cataract surgeries annually.

Key Points: 
  • Harrow Healths wholly owned subsidiary, ImprimisRx, provides surgical dilation (or mydriatic) agents for more than 250,000 cataract surgeries annually.
  • Harrow Health also holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries.
  • Harrow Health also owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals.
  • For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com .